Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
13-valent Pneumoccocal Conjugate Vaccine · 1 trial · 1 indication
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 1 to 1 month after 13vPnC Dose 2 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 1 and after 13vPnC Dose 2 blood draws. Here number of participants analyzed signifies the evaluable immunogenicity population and "N" signifies participants with a determinate IgG antibody concentration for the given serotype at both 1 Month After 13vPnC Dose 1 and 1 Month After 13vPnC Dose 2 blood draws. Participants may be represented in more than 1 category.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| 13-valent Pneumoccocal Conjugate Vaccine | BIOLOGICAL | 2 doses of 13vPnC will be administered by intramuscular injection separated by approximately 6 months. |
Inclusion Criteria: * Male or female subject between the ages of \>=6 to \<18 years. * Diagnosis of SCD * 23vPS vaccination at least 6 months prior to enrollment. Exclusion Criteria: * Previous vaccination with pneumococcal conjugate vaccine. * Previous reaction to any vaccine or vaccine-related ...
The 13-valent Pneumococcal Conjugate Vaccine is a vaccine developed by Pfizer, Inc. (ticker: PFE) for pneumococcal conjugate vaccination. It is designed to protect against pneumococcal disease and has been studied in children with sickle cell disease, a population at elevated risk for pneumococcal infections.
The 13-valent Pneumococcal Conjugate Vaccine is used for pneumococcal conjugate vaccination. It has been evaluated in a Phase 3 study in children with sickle cell disease, a group at higher risk of pneumococcal infection. The vaccine is intended to provide protection against the pneumococcal serotypes included in its formulation.
Pfizer, Inc. (ticker: PFE) is the developer of the 13-valent Pneumococcal Conjugate Vaccine. Pfizer is a global pharmaceutical company that discovers, develops, and manufactures vaccines and medicines across multiple therapeutic areas, including infectious disease.
The 13-valent Pneumococcal Conjugate Vaccine has been studied in a Phase 3 clinical trial. That trial, NCT00918580, is completed. The vaccine is an investigational product in the context of this development program and is not described as approved in the available information.
The 13-valent Pneumococcal Conjugate Vaccine has been evaluated in one completed Phase 3 trial, NCT00918580, titled "Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease." The trial enrolled 158 participants across the United States, Egypt, France, Italy, Lebanon, Saudi Arabia, and the United Kingdom.